Patient global impression of severity (PGI-S) scoring

DIAGNOSTIC_TEST2 trials

Sponsors

Kamari Pharma Ltd

Conditions

Pachyonychia CongenitaPunctate Palmoplantar Keratoderma Type 1

Phase 1

Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases

CompletedNCT05435638

Kamari Pharma LtdPachyonychia Congenita, Punctate Palmoplantar Keratoderma Type 1

Start: 2022-07-17End: 2024-09-05Updated: 2025-01-07

Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC

CompletedNCT05956314

Kamari Pharma LtdPachyonychia Congenita, Punctate Palmoplantar Keratoderma Type 1

Start: 2023-03-06End: 2024-11-07Updated: 2025-01-15